Global Information
회사소개 | 문의 | 비교리스트

프로톤 펌프 억제제(PPI) 시장(2020-2026년)

Proton Pump Inhibitors (PPI) Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949612
페이지 정보 영문
가격
US $ 3,600 ₩ 4,230,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,640,000 Printable PDF (Enterprise License)


프로톤 펌프 억제제(PPI) 시장(2020-2026년) Proton Pump Inhibitors (PPI) Market 2020-2026
발행일 : 2020년 06월 페이지 정보 : 영문

세계의 프로톤 펌프 억제제 시장은 예측기간 중 크게 성장할 것으로 추정됩니다. 시장 성장을 촉진하는 주요 요인에는 주스, 식품 등의 산성 섭취물이 식도로 이동할 때 소화 문제가 발생하는 점이 포함됩니다. GERD(위식도역류증)은 모든 연령층의 사람들에게 영향을 미치고, 천식 환자는 GERD를 발병할 위험이 높아집니다. 또한 소화성 궤양 수 증가, 위산 문제 및 신규 전달 시스템 수요 증가에 의해 시장 성장이 가속하고 있습니다.

세계의 프로톤 펌프 억제제(PPI) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 종류·의약품 종류·지역별 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요, 시장 기회 등 체계적인 정보를 제공합니다.

목차

제1장 보고서 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 인사이트와 현재 시장 동향
  • 규칙과 규제

제3장 경쟁 상황

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • AstraZeneca PLC
    • Takeda Pharmaceuticals Co. Ltd.
    • Pfizer, Inc.
    • Bayer AG
    • Janssen Pharmaceutical, Inc.(Johnson&Johnson Service Inc.의 일부)

제4장 시장 결정요인

  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회

제5장 시장 세분화

  • 종류별
    • Esomeprazole
    • Omeprazole
    • Dexlansoprazole
    • Pantoprazole
    • Rabeprazole
    • Lansoprazole
    • 기타
  • 의약품 종류별
    • 시판약
    • 처방전

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제7장 기업 개요

  • Alkem Laboratories, Ltd.
  • AstraZeneca PLC
  • Aurobindo Pharma, Ltd.
  • Bayer AG
  • Cadila Healthcare, Ltd.
  • Chongqing LUMMY Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals, Inc.
  • Janssen Pharmaceutical, Inc.(A Part ofJohnson & Johnson Service Inc.)
  • Lannett Company, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Procter & Gamble Co.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries, Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceuticals Industries, Ltd.
KSM 20.08.18

LIST OF TABLES

  • 1. GLOBAL PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL ESOMEPRAZOLEMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL OMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL DEXLANSOPRAZOLEMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL PANTOPRAZOLE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL RABEPRAZOLE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL LANSOPRAZOLE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHER PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2019-2026 ($ MILLION)
  • 10. GLOBAL OVER THE COUNTER PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL PRESCRIPTIONPROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2019-2026 ($ MILLION)
  • 16. EUROPEAN PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 17. EUROPEAN PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 18. EUROPEAN PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2019-2026 ($ MILLION)
  • 22. REST OF THE WORLD PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BYADMINISTRATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PROTON PUMP INHIBITORS MARKET SHARE BY TYPE, 2019VS 2026 (%)
  • 2. GLOBAL PROTON PUMP INHIBITORS MARKET SHARE BY ADMINISTRATION, 2019VS 2026 (%)
  • 3. GLOBAL PROTON PUMP INHIBITORS MARKET SHARE BY GEOGRAPHY, 2019VS 2026 (%)
  • 4. US PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD PROTON PUMP INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)

Global Proton Pump Inhibitors (PPI) Market Size, Share & Trends Analysis Report, by Type (Esomeprazole, Omeprazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Lansoprazole and other), by Administration (Over the Counter and Prescription) and Forecast Period, 2020-2026

The global proton pump inhibitors market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include the digestion problem occurs when acidic intakes such as juices, food and converts into the esophagus. GERD affects all age group people, where people with asthma havea higher risk of developing GERD. Moreover, the increase in the number of peptic ulcers, gastric acid problems and rising demand fornovel delivery systems accelerating the market growth.

The global proton pump inhibitors market is segmented based on type and administration. Based on type, the market is classified intoesomeprazole, omeprazole, dexlansoprazole,pantoprazole, rabeprazole, lansoprazole, and other. Based on administration, the market is classified into OTC and prescription. Pfizer recommended Nexium as an OTC product in most of the European countries such as France, Germany, and Italy due to increase in the consumption of esomeprazole drug.Geographically, the global Proton Pump Inhibitors market is segmented into North America, Europe, Asia-Pacific, and Rest of the World.Due to the increase in the number of gastrointestinal problems andthe continuous production of new product is accelerating the market.

The major companies providing PPI includeAstraZeneca PLC, Takeda Pharmaceuticals Co. Ltd., Pfizer, Inc., Bayer AG, Janssen Pharmaceutical, Inc. (A Part of Johnson & Johnson Service Inc.), Aurobindo Pharma, Ltd., Eisai Co., Ltd., Procter & Gamble Co., and Sanofi S.A. These players adopt various strategies in order to stay competitive in the market and expand their market share.

Research Methodology

The market study of the global PPI market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity toour reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

  • Global Proton Pump InhibitorsMarket Research and Analysisby Type
  • Global Proton Pump InhibitorsMarket Research and Analysisby Administration

The Report Covers:

  • Comprehensive research methodologies of the global proton pump inhibitorsmarket.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global proton pump inhibitors market.
  • Insights about market determinants which are stimulating the global proton pump inhibitorsmarket.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Takeda Pharmaceuticals Co. Ltd.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Pfizer, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Bayer AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Janssen Pharmaceutical, Inc. (A Part of Johnson & Johnson Service Inc.)
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Proton Pump Inhibitors Market by Type
    • 5.1.1. Esomeprazole
    • 5.1.2. Omeprazole
    • 5.1.3. Dexlansoprazole
    • 5.1.4. Pantoprazole
    • 5.1.5. Rabeprazole
    • 5.1.6. Lansoprazole
    • 5.1.7. Other
  • 5.2. Global Proton Pump Inhibitors Market by Administration
    • 5.2.1. Over the Counter
    • 5.2.2. Prescription

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Alkem Laboratories, Ltd.
  • 7.2. AstraZeneca PLC
  • 7.3. Aurobindo Pharma, Ltd.
  • 7.4. Bayer AG
  • 7.5. Cadila Healthcare, Ltd.
  • 7.6. Chongqing LUMMY Pharmaceutical Co., Ltd.
  • 7.7. Eisai Co., Ltd.
  • 7.8. GlaxoSmithKline PLC
  • 7.9. Glenmark Pharmaceuticals, Inc.
  • 7.10. Janssen Pharmaceutical, Inc. (A Part ofJohnson & Johnson Service Inc.)
  • 7.11. Lannett Company, Inc.
  • 7.12. Novartis AG
  • 7.13. Pfizer, Inc.
  • 7.14. Procter & Gamble Co.
  • 7.15. Sanofi S.A.
  • 7.16. Sun Pharmaceutical Industries, Ltd.
  • 7.17. Takeda Pharmaceutical Co. Ltd.
  • 7.18. Teva Pharmaceuticals Industries, Ltd.
Back to Top
전화 문의
F A Q